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Abstract
Background: Endogenous retroviruses (ERVs) and ERV-like sequences comprise 8% of the human genome. A
hitherto unknown proportion of ERV loci are transcribed and thus contribute to the human transcriptome. A small
proportion of these loci encode functional proteins. As the role of ERVs in normal and diseased biological
processes is not yet established, transcribed ERV loci are of particular interest. As more transcribed ERV loci are
likely to be identified in the near future, the development of a systematic nomenclature is important to ensure
that all information on each locus can be easily retrieved.
Results: Here we present a revised nomenclature of transcribed human endogenous retroviral loci that sorts loci
into groups based on Repbase classifications. Each symbol is of the format ERV + group symbol + unique number.
Group symbols are based on a mixture of Repbase designations and well-supported symbols used in the literature.
The presented guidelines will allow newly identified loci to be easily incorporated into the scheme.
Conclusions: The naming system will be employed by the HUGO Gene Nomenclature Committee for naming
transcribed human ERV loci. We hope that the system will contribute to clarifying a certain aspect of a sometimes
confusing nomenclature for human endogenous retroviruses. The presented system may also be employed for
naming transcribed loci of human non-ERV repeat loci.
Human endogenous retroviruses
Human endogenous retroviruses (ERVs) are remnants of
infections of former exogenous retroviruses. Proviruses
formed by numerous distinct exogenous retroviruses in
the germline genome could be inherited by subsequent
generations. About 8% of the human genome consists of
sequences that are potentially of retroviral origin [1] and
are distributed in about 700,000 different loci. In addi-
tion to proviruses, these sequences include solitary long
terminal repeats (LTRs), nonretroviral sequences flanked
by LTRs that may not be directly derived from infec-
tious retroviruses and sequences similar to LTRs. ERVs
and related sequences are thus part of the repetitive
portions of the human genome, which comprise about
45% of the human genome mass, including mobile DNA
such as L1, Alu and SVA elements.
Detailed analysis of the human genome sequence by
wet-lab and bioinformatics approaches resulted in the
definition of ERV groups, with the number depending
on the methods used for defining groups: 31 groups
were defined by Sperber et al. [2] and Blomberg et al.
[3], 42 groups were defined by Mager and Medstrand
[4], 30 groups were defined by Gifford and Tristem [5]
and several hundred human ERV and LTR families were
defined by Repbase [6].
Almost all human ERV loci no longer encode former
retroviral proteins because of their ancient incorporation
into the host genome and thus accumulation of non-
sense mutations. Many loci are missing large proviral
portions, and most loci have been reduced to so-called
solitary LTRs by homologous recombination between
proviral LTRs. For more detailed information on human
ERVs, we refer interested readers to recent reviews on
the topic and the references therein [7-10].
While protein coding capacity is very limited, many
human ERV loci still are transcribed and usually are
initiated by promoter sequences within the proviral
LTRs. Obviously, mutations within LTRs have not yet
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principle, promoters in flanking, non-ERV sequences
may also contribute to transcription of those loci.
Probably every human tissue and cell type, diseased or
not, contains ERV transcripts [11,12]. More than a sin-
g l eE R Vg r o u pi su s u a l l yf o u n dt r a n s c r i b e d ,a n dp a t -
terns of transcribed ERV groups differ between tissue
and cell types. Transcription of ERV loci is thus regu-
lated in some way. While expression of ERV sequences
has been associated with a number of human diseases,
such as germ cell tumours, melanoma and multiple
sclerosis, the involvement of ERVs in human diseases
remains to be elucidated. On the other side, some ERV
loci very likely provide important biological functions,
such as the syncytin [13] and syncytin 2 loci [14],
referred to herein as ERVW-1 and ERVFRD-1, respec-
tively. Other loci harbouring only partial open reading
frames, such as a recently characterized HERV-W
locus on chromosome Xq22.3 [15] (ERVW-2), may
likewise produce partial retroviral proteins with poten-
tial biological functions. It is therefore of particular
interest which ERV loci actually contribute to the
human transcriptome.
Recent studies have identified transcribed ERV loci in
normal and diseased human cells and tissues by means
of reassigning ERV cDNA sequences to individual loci
in the human reference genome sequence, employing
characteristic nucleotide differences between individual
loci of a regarded ERV group. Many more transcribed
ERV loci are likely to be identified in future studies. It is
therefore necessary to introduce a nomenclature for
transcribed human ERV sequences.
Previous nomenclature used in the literature
The lack of an established nomenclature for tran-
scribed ERV elements has led to confusion within the
literature. These problems were previously reviewed in
detail [16]. ERVs have been classified into groups (for-
merly known as “families”, which is heresy to virolo-
gists because “family” refers to Retroviridae), although
different classification systems have been used. For
instance, some groups have been defined initially by
molecular genetics means, others by sequence similar-
ity and others by primer binding site sequences. Chan-
ging amounts of sequence information also showed
that some ERV groups’ designations needed to be
revised. Different names have been used for the same
ERV group. Likewise, individual loci have been referred
to using a variety of different symbols (for example,
see the aliases listed in Table 1 for the ERVK-6 locus).
The use of different symbols for the same locus makes
it difficult to retrieve all information on that particular
locus.
Previous ERV nomenclature and the Human
Genome Organisation Gene Nomenclature
Committee
The Human Genome Organisation (HUGO) Gene
Nomenclature Committee (HGNC) works under the
auspices of HUGO and is the only worldwide authority
that assigns standardised nomenclature to human genes
[17]. The HGNC has previously focused on approving
nomenclature for protein-coding genes, pseudogenes,
phenotypes and noncoding RNA. In the past, the com-
mittee has approved symbols for specific human ERVs
only at the request of individual researchers. The sym-
bols did not follow a systematic nomenclature: some
symbols were of a simple format (for example, ERV1),
some provided information on the group to which the
E R Vb e l o n g e d( f o re x a m p l e ,E R V K 2 )a n do t h e r s
included information on proteins encoded by the ERV
(for example, ERVWE1 (endogenous retroviral family
W, env(C7), member 1)). On reviewing the literature, it
was clear that (1) many of the most frequently published
loci were not represented by HGNC symbols, (2) by fol-
lowing more than one system, HGNC symbols were not
serving the community, and (3) the nomenclature
needed both updating and expansion.
HGNC editors curate relevant information for each
gene that has approved nomenclature. In addition to
approving a gene symbol and name for each transcribed
human ERV, the HGNC records all known symbol
aliases so that information on each gene can be
retrieved using any known symbol. HGNC entries also
include the chromosomal location of the ERV locus,
links to GenBank, European Molecular Biology Labora-
tory (EMBL) and DNA Databank of Japan (DDBJ)
sequence records and links to at least one PubMed
reference. Where appropriate, links are also provided to
annotation projects at both the genomic and proteomic
levels. HGNC names are propagated to other major bio-
logical databases, such as Ensembl, UniProt and Entrez
Gene. Therefore, this new nomenclature will provide a
useful resource that is currently unavailable to the ERV
community and other researchers concerned with ERVs.
A gene-based nomenclature
T h ep r i m a r yd e f i n i t i o no fag e n eu s e db yt h eH G N Ci s
“a DNA segment that contributes to phenotype/func-
tion” [18]. It is beyond the scope of this nomenclature
effort to standardise the nomenclature of ERVs in gen-
eral or to attempt to name every ERV element in the
genome. As discussed above, there is evidence that
some human ERVs encode functional proteins and that
some encode transcripts and/or proteins which may be
associated with disease, so the transcriptionally active
loci come under the remit of the HGNC for naming.
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Symbol Name Chromosome
location
Aliases Representative GenBank
accession numbers
Sources
ERVK-1
a endogenous retrovirus group K,
member 1
1p31.1 c1_A FN806826, BQ304053 [23]
[24]
ERVK-2 endogenous retrovirus group K,
member 2
3p25.3 c3_A FN806829, EF153331 [23]
ERVK-3 endogenous retrovirus group K,
member 3
3q13.2 c3_B FN806830 [23]
ERVK-4 endogenous retrovirus group K,
member 4
3q21.2 c3_C, ERVK4, HERV-K(I) FN806831 [23]
[25]
ERVK-5 endogenous retrovirus group K,
member 5
3q12.3 ERVK5, HERV-K(II) CF227259, AK021866 [24]
[25]
ERVK-6 endogenous retrovirus group K,
member 6
7p22.1 c7_A, ERVK6, HERV-K108, HERV-K(HML-2.
HOM), envK2, HERV-K(C7)
FN806837, AY371029, X82271,
AF080233
[23]
[26]
[27]
ERVK-7 endogenous retrovirus group K,
member 7
1q22 c1_B, ERVK7, HERV-K102 FN806827, EF153338, S46404,
DQ069911
[23]
[28]
ERVK-8 endogenous retrovirus group K,
member 8
8p23.1 c8_A, ERVK8, HERV-K115, envK6 FN806840 [23]
[27]
[29]
ERVK-9 endogenous retrovirus group K,
member 9
6q14.1 c6_A, HERV-K109, envK4 FN806836, AF080234,
AY371030
[23]
[26]
[27]
[28]
ERVK-10 endogenous retrovirus group K,
member 10
5q33.3 c5_A, HERV-K10 FN806835, AF080231,
CN345079
[23]
[24]
[26]
ERVK-11 endogenous retrovirus group K,
member 11
3q27.2 c3_E, N8.4, HML-2A FN806833, AF080232,
AF080229, U87590
[23,26]
ERVK-12 endogenous retrovirus group K,
member 12
4q32.3 c4_A FN806834, EF153341 [23]
ERVK-13 endogenous retrovirus group K,
member 13
3q24 c3_D FN806832 [23]
ERVK-14 endogenous retrovirus group K,
member 14
7q22.1 c7_B FN806838 [23]
ERVK-15 endogenous retrovirus group K,
member 15
7q34 c7_C, P1.10 FN806839, U87594 [23]
ERVK-16 endogenous retrovirus group K,
member 16
10p14 c10_A. M3.8 FN806841, EF543114, U87587 [23]
[27]
[30]
ERVK-17 endogenous retrovirus group K,
member 17
10q24.2 c10_B FN806842, AF080230 [23]
[26]
ERVK-18 endogenous retrovirus group K,
member 18
1q23.3 c1_C, HERV-K18 FN806828 [23]
[31]
ERVK-19 endogenous retrovirus group K,
member 19
19q11 P1.8, HERV-K(C19), envK3 U87593 [27,30]
[31]
ERVK-20 endogenous retrovirus group K,
member 20
11q23.3 c11_B FN806844 [23]
ERVK-21 endogenous retrovirus group K,
member 21
12q14.1 c12_A, envK1 FN806845, U32496 [23]
[27]
ERVK-22 endogenous retrovirus group K,
member 22
19p13.3 c19_A FN806846, EF153351 [23]
ERVK-23 endogenous retrovirus group K,
member 23
21q21.1 c21_A FN806847, EF543113 [23]
ERVK-24 endogenous retrovirus group K,
member 24
22q11.21 c22_A, HERV-K101 FN806848, AU124350,
AA580921, AW812040
[23]
[28]
ERVK-25 endogenous retrovirus group K,
member 25
11q22.1 c11_A FN806843, CF227268,
AW818206
[23]
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ERVK3-1
b endogenous retrovirus group K3,
member 1
19q13.43 HERV-K(HML6-1) AK054868, BC010118,
BC011670
[32]
ERVK3-2 endogenous retrovirus group K3,
member 2
14q24.2 HML6-c14 AK027828, AK096726,
CR591084
[32]
ERVK3-3 endogenous retrovirus group K3,
member 3
5q13.2 HML6-c5 FR714893 [33]
ERVK3-4 endogenous retrovirus group K3,
member 4
11p15.4 HML6-c11 FR714894 [33]
ERVK3-5 endogenous retrovirus group K3,
member 5
12q24.12 HML6-c12 FR714895 [33]
ERVK3-6 endogenous retrovirus group K3,
member 6
19q13.41 HML6-c19A FR714896 [33]
ERVK3-7 endogenous retrovirus group K3,
member 7
19p13.2 HML6-c19B FR714897 [33]
ERVK3-8 endogenous retrovirus group K3,
member 8
20p11.21 HML6-c20 FR714898 [33]
ERVFRD-1 endogenous retrovirus group
FRD, member 1
6p24.2 HERV-FRD, envFRD, ERVFRDE1, syncytin 2 AK075092, AK123938,
AY358244
[24]
[27]
[34]
ERVFRD-2
c endogenous retrovirus group
FRD, member 2
19q13.41 FLJ45949 AK127846
ERV3-1 endogenous retrovirus group 3,
member 1
7q11.21 ERV3, envR AK295189 [24]
[27]
[35]
[36]
ERV3-2
c endogenous retrovirus group 3,
member 2
7q33 KIAA1466 AB040899, AL833192
ERVPABLB-
1
endogenous retrovirus group
PABLB, member 1
3p24.3 envR(b) BQ012865, CF529244,
AI189490
[27]
ERVFC1-1 endogenous retrovirus group
FC1, member 1
7q36.2 envF(c)2 AK124285 [27]
ERVW-1 endogenous retrovirus group W,
member 1
7q21.2 ERVWE1, syncytin 1, enverin, envW, HERV-
W-ENV, HERV-7q, HERV7Q
BG012022, AF208161,
BX391741, BX365066
[13,24]
[27]
[37]
ERVW-2 endogenous retrovirus group W,
member 2
Xq22.3 ERVWE2, Penv-C15 AF127228, FN689795 [38]
ERVW-3 endogenous retrovirus group W,
member 3
3q23 CL4 AF127227 [39]
ERVW-4 endogenous retrovirus group W,
member 4
15q21.3 C187-23 AF123882, EF539878 [38]
[39]
[40]
ERVW-5 endogenous retrovirus group W,
member 5
3q26.32 CL2 AF123881 [39]
ERVW-6 endogenous retrovirus group W,
member 6
11q14.1 AK022306, AB063619 [41]
ERVS71-1 endogenous retrovirus group
S71, member 1
19p13.11 envT CN288807, BQ932595,
BQ941761
[27]
[42]
ERVS71-2 endogenous retrovirus group
S71, member 2
10p11.1 HERV-HC2 AB167270, AB167277 [43]
ERVFH21-1 endogenous retrovirus group
FH21, member 1
7p21.3 HERV-F(XA34) AK023847 [32]
ERVH48-1 endogenous retrovirus group 48,
member 1
21q22.3 C21orf105, HERV-F (type b) BC005107, CR591419 [32]
ERVE-1 endogenous retrovirus group E,
member 1
17q11.2 ERVE1 BC037342, FM212572 [44]
ERVE-2 endogenous retrovirus group E,
member 2
11q13.2 FM212575 [45]
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loci that have been published with individual names, so
it is worth developing a standardised nomenclature for
this subset. The three criteria for being accepted as a
transcriptionally active ERV are as follows: (1) The ERV
must be represented by an mRNA sequence in a public
database, (2) the reported cDNA sequence must map
unambiguously to the reference genome to allow identi-
fication and (3) the sequence must represent a viral
gene rather than solely a solitary LTR. We acknowledge
that there are sources of uncertainty. Many ERVs may
be expressed at a low level [19], a “leakage” which can
be hard to distinguish from perhaps more significant
expression. Groups of recently integrated ERVs may be
highly expressed, but their transcripts may be identical
or almost identical and could be hard to map unam-
biguously. However, these difficulties should not prevent
the naming of ERV loci which fulfil the criteria men-
tioned above. There is one symbol approved per ERV
locus independently of how many viral genes the ERV
may encode.
A systematic ERV nomenclature scheme
The nomenclature scheme described in this paper aims
to be concise so that it is user-friendly. It also aims to
be informative to researchers, including those who are
less familiar with the field. To be informative, the
nomenclature scheme is hierarchical, with each symbol
beginning with the root symbol “ERV” so that the sym-
bols are instantly recognisable and can be grouped
together in searches. Note that many researchers have
published papers using symbols beginning with “HERV”,
but it is against the guidelines of the HGNC ever to use
Hf o r“human” in symbols, mainly because this pre-
cludes the possibility of the nomenclature scheme’s
being extended to other species. Each ERV symbol,
then, includes an identifier that represents the group to
which the ERV belongs.
Table 1 Nomenclature for transcribed human endogenous retrovirus loci (Continued)
ERVE-3 endogenous retrovirus group E,
member 3
8p23.1 FM212573 [45]
ERVE-4 endogenous retrovirus group E,
member 4
6q15 CT-RCC-1 EU137846 [46]
ERVV-1 endogenous retrovirus group V,
member 1
19q13.41 HERV-V1, ENVV1 AK056776, BC104018,
BC104019
[47]
ERVV-2 endogenous retrovirus group V,
member 2
19q13.41 HERV-V2, ENVV2 AI434519, CA417098,
DA863698
[47]
ERVI-1
c endogenous retrovirus group I,
member 1
9q22.1 AK124340, AK124077,
CR614956
ERV18-1
c endogenous retrovirus group 18,
member 1
15q21.3 AK126787
ERVMER61-
1
c
endogenous retrovirus group
MER61, member 1
1q31.3 C1orf99 BC040856
ERVH-1 endogenous retrovirus group H,
member 1
4p15.2 HERV-H4p15.2 EU669866, BC015108 [48]
ERVH-2 endogenous retrovirus group H,
member 2
Xp22.32 HERV-HX EU195218, EU195219 [48]
ERVH-3 endogenous retrovirus group H,
member 3
6q12 HERV-H/F AJ431196 [49]
ERVH-4 endogenous retrovirus group H,
member 4
14q32.2 clone c4.2 U35031, U88895 [50]
ERVH-5 endogenous retrovirus group H,
member 5
10p12.1 clone c14.6 U35033 [50]
ERVH-6 endogenous retrovirus group H,
member 6
Yq11.223 U88898 [50]
ERVH-7 endogenous retrovirus group H,
member 7
14q32.12 BC039675, T67812 [50]
ERV9-1 endogenous retrovirus group 9,
member 1
11q13.2 pTR2 X15673, X15675, X57147 [51]
[52]
aThe ERVK group is referred to as HERV-K(HML-2) according to a nomenclature introduced by Andersson et al. in 1999 [53].
bThe ERVK3 group has been referred
to as HERV-K(HML-6) according to the Andersson et al. classification scheme [53].
cThe following loci have not appeared in publications but have been annotated
by the RefSeq project: ERVFRD-2 (Entrez Gene:388560); ERVI-1 (Entrez Gene ID:100131068); ERV18-1 (Entrez Gene ID:100133791); ERVMER61-1 (Entrez Gene
ID:339476).
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tic, one method of sorting ERVs into groups needed to
be selected. The Repbase system [6] is a widely known,
comprehensive database of repetitive elements that
groups ERVs together on the basis of sequence similar-
ity. RepeatMasker annotations using Repbase designa-
tions are available on the University of California, Santa
Cruz (UCSC) [20], and Ensembl [21] genome browsers,
making these ERV groups highly accessible and recogni-
sable to researchers in the field. Therefore, the nomen-
clature system uses the Repbase classification system for
naming the ERVs within groups. Repbase groups, how-
ever, do not follow a systematic nomenclature and often
contain an unallowable “H” for “human”. When deciding
on the group identifier to be included in each symbol,
we compared Repbase symbols with those that have
appeared frequently in the literature. In cases where
there was a well-supported nomenclature present in the
literature, we used this symbol in place of the Repbase
symbol; for example, we used ERVW instead of the
Repbase group designation HERV17, as we felt that
these would be more likely to be used by the ERV com-
munity. For a comparison of the group symbols used in
the new nomenclature scheme with Repbase designa-
tions, see Table 2.
Finally, each ERV within a particular group is uniquely
identified by a number, for example, ERVK-1. Numbers
are assigned consecutively within each group to make
the nomenclature system expandable. The number is
used to make each symbol unique and has no intrinsic
meaning. ERVK-2 has merely been assigned the next
number following ERVK-1, but this provides no
information on the position of the ERVs within the gen-
ome or the order in which an ERV may have been pub-
lished. The use of numerical identifiers keeps the
symbols as short as possible to encourage widespread
use by researchers. Newly identified transcribed loci will
take the next available consecutive number for their par-
ticular group; for example, if a newly transcribed ERVK
locus is identified, it will take the symbol ERVK-26.
Each symbol is accompanied by an expanded gene name
which clearly and succinctly explains that derivation of
the nomenclature; for example, the full name of
ERVFRD-1 is “endogenous retrovirus group FRD, mem-
ber 1”.
We are aware that the proposed nomenclature scheme
cannot encompass all conceivable (and sometimes
known) unusual structures of ERV loci, such as hybrid
loci consisting of different ERV groups and ERV inser-
tions into existing ERV loci [22]. HGNC, after confer-
ring with researchers who submit newly identified
transcribed loci, will dec i d ew h e t h e ro rh o wt on a m e
such unique loci on a case-by-case basis. For example,
the scheme will not incorporate ERV locus transcripts
that are part of another gene’s transcript, as these ele-
ments will not be considered separate loci.
Table 1 lists transcribed human ERVs that have been
named according to the new nomenclature system. All
ERVs in the table either have been published or have
been annotated by the RefSeq project. An initial list was
sent to a number of researchers in the field for their
comments. The list was expanded as these researchers
suggested more loci. Where no transcript sequence was
available, authors were asked to submit representative
sequences to the GenBank, EMBL and DDBJ databases.
We encourage researchers to contact the HGNC if they
know of further ERVs that can be included in the
scheme.
Finally, although only human gene nomenclature is
under the remit of the HGNC, we wish to mention that
the naming system introduced here for transcribed
ERVs could, in principle, also be applied to other, non-
ERV repetitive sequences in the human genome, as well
as to repetitive DNA in nonhuman species. Future
research will probably reveal numerous transcribed
repetitive DNA sequences in various species. Judged just
from ERV designations in different species, a standar-
dised naming system for transcribed repeat loci may be
highly beneficial to avoid future confusion.
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